Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
Agammaglobulinaemia Tyrosine Kinase
/ antagonists & inhibitors
Antibodies, Viral
/ biosynthesis
Antigens, Viral
/ immunology
COVID-19
/ complications
COVID-19 Vaccines
/ immunology
Follow-Up Studies
Humans
Immunization, Secondary
Immunocompromised Host
Immunogenicity, Vaccine
Immunoglobulin G
/ biosynthesis
Neoplasms
/ complications
Prospective Studies
Protein Kinase Inhibitors
/ adverse effects
Rituximab
/ adverse effects
SARS-CoV-2
/ immunology
Seroconversion
Spike Glycoprotein, Coronavirus
/ immunology
Vaccination
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
pubmed:
29
11
2021
medline:
20
1
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.
Identifiants
pubmed: 34838186
pii: S1535-6108(21)00606-1
doi: 10.1016/j.ccell.2021.11.006
pmc: PMC8595142
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Protein Kinase Inhibitors
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Rituximab
4F4X42SYQ6
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
BTK protein, human
EC 2.7.10.2
Types de publication
Letter
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-5Subventions
Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189859
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests R.A.S. serves as a consultant with Morphosys and Miragen and is on the faculty at Physicians’ Education Research. A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company; has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene; and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests.
Références
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Blood. 2022 Mar 10;139(10):1439-1451
pubmed: 34662390
Cancer Cell. 2021 Oct 11;39(10):1297-1299
pubmed: 34509182
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856
Leuk Lymphoma. 2022 Oct;63(10):2484-2488
pubmed: 35593019
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951